Comparative Efficacies of Two Antimony Regimens To Treat Leishmania braziliensis -Induced Cutaneous Leishmaniasis in Rhesus Macaques ( Macaca mulatta )-Reference-Cited by-同舟云学术

Comparative Efficacies of Two Antimony Regimens To Treat Leishmania braziliensis -Induced Cutaneous Leishmaniasis in Rhesus Macaques ( Macaca mulatta )

Published:2010-01 Issue:1 Volume:54 Page:502-505
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Grimaldi G.¹,Porrozzi R.¹,Friedrich K.²,Teva A.¹,Marchevsky R. S.³,Vieira F.⁴,Miekeley N.⁴,Paumgartten F. J. R.²

Affiliation:

1. Laboratório de Pesquisa em Leishmaniose, Instituto Oswaldo Cruz

2. Laboratório de Toxicologia Ambiental, Escola Nacional de Saúde Pública

3. Laboratório de Neurovirulência, Instituto de Tecnologia em Imunobiológicos, Fiocruz

4. Departamento de Química, Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro, Brazil

Abstract

ABSTRACT This study compared the efficacies of two N -methylglucomine antimoniate (MA) dose regimens for treating macaques with Leishmania braziliensis -induced chronic skin disease. Whereas all animals treated with the full dose (20 mg MA/kg/day) were cured, 50% of the monkeys receiving a low-dose regimen (5 mg MA/kg/day) relapsed. The antimony concentrations in macaque plasma and tissue samples were greater in the full-dose group than in that receiving a subtherapeutic MA regimen. Our data also suggest the presence of drug-induced hepatic pathology.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00858-09

Reference15 articles.

1. Azeredo-Coutinho, R. B. G., S. C. F. Mendonça, H. Callahan, A. C. Portal, and M. Grögl. 2007. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (Glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J. Parasitol.93:688-693.

2. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis.10:560-586.

3. Chulay, J. D., L. Fleckenstein, and D. H. Smith. 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg.82:69-72.

4. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol.19:502-508.

5. Cruz, A., P. M. Rainey, B. L. Herwaldt, G. Stagni, R. Palacios, R. Trujillo, and N. G. Saravia. 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J. Infect. Dis.195:602-608.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the drug screening approaches in leishmaniasis;International Immunopharmacology;2023-01

2. Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis;The American Journal of Tropical Medicine and Hygiene;2020-04-01

3. CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis;PLOS Neglected Tropical Diseases;2020-02-28

4. Leishmaniasis in non‐human primates: Clinical and pathological manifestations and potential as reservoirs;Journal of Medical Primatology;2019-10-08

5. Leishmanicidal effect of antiparasitic photodynamic therapy—ApPDT on infected macrophages;Lasers in Medical Science;2017-07-27